Uncategorized

‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing

Published

5 months ago

on

June 12, 2026

By

Temp User

Elon Musk’s SpaceX may be igniting global headlines with the company’s astronomical IPO, but biotech listings saw their own record-breaker this week.

Related Topics:

Leave a Reply

Uncategorized8 months ago

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Endpoints News8 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized6 months ago

Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
Uncategorized6 months ago

Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
Uncategorized5 months ago

Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
Fierce Biotech8 months ago

Scientists turn pig semen extract into eye drops that kill cancer in mice

Exit mobile version